Insilico Medicine has marked a significant milestone by completing first-in-human dosing of its AI-generated NLRP3 inhibitor, ISM8969, in collaboration with Hygtia Therapeutics. This Phase I clinical trial aims to evaluate the safety and pharmacokinetics of ISM8969, which targets chronic neuroinflammation linked to CNS disorders like Parkinson's disease.
The Phase I study is being conducted in Australia and will involve 100 participants, including healthy individuals and those at risk of cardiovascular disease. It will assess the drug's ability to penetrate the central nervous system (CNS) by collecting cerebrospinal fluid samples, which will help characterize its pharmacokinetic and pharmacodynamic profile. This data is crucial for future dose selection and therapeutic relevance.
ISM8969 is designed to inhibit the NLRP3 inflammasome, which, when overly activated, contributes to neuroinflammation and neurodegenerative diseases. Early preclinical studies indicate that ISM8969 has a favorable drug profile, demonstrating efficacy in various mouse models and the ability to cross the blood-brain barrier, setting it apart from other NLRP3 inhibitors.
Insilico's collaboration with Hygtia Therapeutics involves a shared stake in the program, with Insilico leading the clinical trial efforts. This partnership is part of Insilico's broader strategy to leverage AI in drug development, significantly reducing the time required to nominate preclinical candidates. As the company continues to enhance its AI platform, it aims to redefine drug discovery efficiency and address unmet medical needs across multiple therapeutic areas.